Levothyroxine Sodium Tablets USP, 175 mcg, packaged in a) 90-count bottles (NDC 0378-1817-77) and b) 1000-count bottles (NDC 0378-1817-10), Rx only, Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A.
Published December 18, 2024 · Recall initiated: November 18, 2024
Summary
FDA records drug Class II recall D-0121-2025, published December 18, 2024 and initiated November 18, 2024. Recalling firm: Viatris Inc; Status: Ongoing; Reported quantity: 19, 549 bottles; Lot: Lot #: a) 3192915, 8172108, Exp. Date Mar 2025; b) 3208680, Exp. Date Sep 2025. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Superpotent Drug and Subpotent Drug: potency failures obtained
What to do
Voluntary: Firm initiated · Letter
Get an email if LEVOTHYROXINE SODIUM has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- LEVOTHYROXINE SODIUM
- Manufacturer
- Viatris Inc
- Distributor
- Nationwide within the United States and Puerto Rico
- Lot
- Lot #: a) 3192915, 8172108, Exp. Date Mar 2025; b) 3208680, Exp. Date Sep 2025
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDALevothyroxine Sodium Tablets, USP, 50 mcg (0.05 mg), 1000-count bottles, Rx Only, Manufactured for: AccordSeptember 2, 2026
- FDALevothyroxine Sodium Tablets, USP, 88 mcg (0.088 mg), 1000-count bottles, Rx Only, Manufactured for: AccordSeptember 2, 2026
- FDALevothyroxine Sodium Tablets, USP, 25 mcg (0.025 mg), 1000-count bottles, Rx Only, Manufactured for: AccordSeptember 2, 2026
- FDALevothyroxine Sodium Tablets, USP, 300 mcg (0.3 mg), 90-count bottles, Rx Only, Manufactured for: AccordSeptember 2, 2026
- FDALevothyroxine Sodium Tablets USP, 150 mcg, packaged in a) 90-count bottles (NDC 0378-1815-77) and b)December 18, 2024
- FDALevothyroxine Sodium Tablets USP, 200 mcg, packaged in a) 90-count bottles (NDC 0378-1819-77) and b)December 18, 2024
Questions about this recall
Was Levothyroxine Sodium Tablets USP, 175 mcg, packaged in a) 90-count bottles (NDC 0378-1817-77) and b) 1000-count bottles (NDC 0378-1817-10), Rx only, Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. recalled?
Yes. FDA published recall D-0121-2025 on December 18, 2024. Reported hazard: Superpotent Drug and Subpotent Drug: potency failures obtained
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: LEVOTHYROXINE SODIUM.